Peptic ulcer: new therapies, new diseases.
Although hospitalizations and deaths attributable to peptic ulcer have decreased notably during the past decade, it is not certain whether this decrease is because of reduced incidence of new cases or changes in other factors, such as the severity of the disease. Several genetic traits associated with peptic ulcer have been recognized. Hyperpepsinogenemia I is the most prevalent. Peptic ulcer is a heterogeneous group of disorders with multiple genetic and environmental causes. One manifestation of the diversity of ulcer disease is the variety of physiologic abnormalities seen in patients. The use of endoscopy has enabled more reliable evaluation of new treatments. Histamine H2-receptor antagonists are the dominant mode of treatment, but increasing attention is being given to agents that enhance the resistance of the mucosa to injury, such as prostaglandins. Because of the lower frequency of side effects, proximal gastric vagotomy is gradually replacing truncal vagotomy with drainage. The possibility that endoscopic treatments, such as laser coagulation, may reduce mortality from bleeding ulcers is being investigated.
D004381:Duodenal Ulcer / Q000601:surgery; D004724:Endoscopy; D005744:Gastric Acid; D005753:Gastric Mucosa / Q000473:pathology; D005769:Gastrointestinal Motility; D006489:Hemostatic Techniques; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology; D010437:Peptic Ulcer / Q000145:classification / Q000503:physiopathology / Q000628:therapy*; D010438:Peptic Ulcer Hemorrhage / Q000628:therapy; D011453:Prostaglandins / Q000502:physiology
D011453:Prostaglandins